US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.
According to Zhitong Finance APP, on Friday, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market. As of press time, the stock was down over 10%, trading at $10.77. The IPO price was $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core pipeline drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor, mainly targeting patients with uncontrolled or resistant hypertension, and is currently undergoing Phase IIb clinical trials. This drug helps vasodilation and lowers blood pressure by enhancing nitric oxide signaling in blood vessels, and its exclusive global development license is from the French pharmaceutical giant Sanofi-Aventis (SNY.US).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Needham raises CrowdStrike target price to $310
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Crypto prices
More
